PP
GILD icon

PagnatoKarp Partners’s Gilead Sciences GILD Stock Holding History

PagnatoKarp Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,040
Closed -$227K – 47
2020
Q1 		$227K Sell
3,040
-215
-7% -$14.9K 0.06% 144
2019
Q4 		$212K Sell
3,255
-135
-4% -$8.79K 0.04% 175
2019
Q3 		$215K Buy
3,390
+213
+7% +$13.9K 0.04% 173
2019
Q2 		$215K Buy
+3,177
New +$209K 0.05% 169
2018
Q4 		– Sell
-2,947
Closed -$228K – 180
2018
Q3 		$228K Buy
2,947
+119
+4% +$8.99K 0.07% 152
2018
Q2 		$200K Buy
+2,828
New +$200K 0.06% 141

Other funds holding GILD

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

PagnatoKarp Partners's GILD Position: Q2 2020 in Review

PagnatoKarp Partners sold out of Gilead Sciences (GILD) in Q2 2020, closing a stake of 3,040 shares — an estimated $227K sold.

PagnatoKarp Partners first reported a position in GILD in Q2 2018 and held it in 6 quarters. The position peaked at $228K in Q3 2018. 1,626 funds tracked by Wall St. Rank hold GILD as of Q2 2020.

  • PagnatoKarp Partners reported no remaining Gilead Sciences position as of Q2 2020 after selling out during the quarter.
  • PagnatoKarp Partners sold 3,040 Gilead Sciences shares in Q2 2020, an estimated $227K.
  • PagnatoKarp Partners first reported a position in Gilead Sciences in Q2 2018 and held it in 6 quarters.
  • PagnatoKarp Partners's Gilead Sciences position peaked at $228K in Q3 2018.
  • 1,626 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2020.

Based on PagnatoKarp Partners's 13F filing for Q2 2020.